3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
No longer available
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
7
Stomach Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
HER2-positive Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Adenocarcinoma Of Esophagus
1
Interventions
Temozolomide
94
Radiotherapy
59
Bevacizumab
59
Radiosurgery
41
Carboplatin
27
Irinotecan
26
Magnetic Resonance Spectroscopy
25
Surgical Procedures, Operative
23
Etoposide
22
Carmustine
20
Filgrastim
18
Erlotinib Hydrochloride
17
Cyclophosphamide
16
Cisplatin
16
Vincristine
15
Lomustine
15
Lapatinib
15
Sorafenib
13
Radiation
13
Trastuzumab
12
Nivolumab
12
Imatinib Mesylate
12
Thalidomide
11
Surveys and Questionnaires
11
Granulocyte Colony-Stimulating Factor
11
Radiotherapy, Intensity-Modulated
10
Aminolevulinic Acid
10
temsirolimus
9
Topotecan
9
Thiotepa
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Brain Neoplasms
×
tucatinib
×
Clear all
NCT02614794
2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2
Completed
612 enrolled
30 charts
1 FDA